Recent advances in drug-induced neuropathies. Peltier AC, Russell JW (2002) Curr Opin Neurol 15: 633-8 Phenotypic alterations in fibroblasts and fibrosarcoma cells that overexpress latent transforming growth factor-beta 1. Beauchamp RD, Sheng HM, Bascom CC, Miller DA, Lyons RM, Torre-Amione G, Moses HL (1992) Endocrinology 130: 2476-86 The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Wilson S, Greer B, Hooper J, Zijlstra A, Walker B, Quigley J, Hawthorne S (2005) Biochem J 388: 967-72 Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. Coffey RJ, Leof EB, Shipley GD, Moses HL (1987) J Cell Physiol 132: 143-8 Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction. Chang SY, Yu DS, Sherwood ER, Kozlowski JM, Lee C (1992) J Urol 147: 1147-50 Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. Kim JH, Sherwood ER, Sutkowski DM, Lee C, Kozlowski JM (1991) J Urol 146: 171-6 The anti-parasitic agent suramin and several of its analogues are inhibitors of the DNA binding protein Mcm10. Paulson CN, John K, Baxley RM, Kurniawan F, Orellana K, Francis R, Sobeck A, Eichman BF, Chazin WJ, Aihara H, Georg GI, Hawkinson JE, Bielinsky AK (2019) Open Biol 9: 190117
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.